Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.

Another important aspect to consider is the higher prevalence of prediabetes in the empagliflozin arm at baseline (randomization visit) (Table 1 ), which could represent a conservative bias that could have obscured a positive result, since the worsening of glucose tolerance status reached borderline significance in favour of empagliflozin.

also in 93 other papers